Polymer-lipid hybrid systems: Merging the benefits of polymeric and lipid-based nanocarriers to improve oral drug delivery

Expert Opinion on Drug Delivery

Volumn 13, Issue 5, 2016, Pages 691-707

  Rao, Shasha ^a   Prestidge, Clive A ^a  

^a UNIVERSITY OF SOUTH AUSTRALIA   (Australia)

Author keywords

Bioavailability; mucus and mucosal barriers; oral drug delivery; polymer lipid hybrid; proteins and peptides; vaccine

Indexed keywords

CHITOSAN; CHITOSAN NANOPARTICLE; MACROGOL; MACROGOL 2000; NANOCARRIER; PHOSPHATIDYLCHOLINE; POLOXAMER; POLYMER; SOLID LIPID NANOPARTICLE; DRUG; LIPID; MACROGOL DERIVATIVE; NANOPARTICLE;

CROSS LINKING; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG DELIVERY SYSTEM; DRUG HALF LIFE; DRUG PENETRATION; DRUG RELEASE; DRUG SOLUBILITY; DRUG TRANSPORT; DRUG UPTAKE; ENZYMATIC DEGRADATION; HYDROPHILICITY; INTESTINE ABSORPTION; LIPID BILAYER; LIPID VESICLE; LIPOPHILICITY; LIPOSOMAL DELIVERY; MONONUCLEAR PHAGOCYTE; NANOENCAPSULATION; ORAL DRUG ADMINISTRATION; PARTICLE SIZE; PHYSICAL CHEMISTRY; POLYMERIZATION; REVIEW; STATIC ELECTRICITY; STEREOSPECIFICITY; SURFACE PROPERTY; SYSTEMIC CIRCULATION; THERAPY EFFECT; VOLUME OF DISTRIBUTION; ZETA POTENTIAL; ANIMAL; BIOAVAILABILITY; CHEMISTRY; HUMAN;

ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CHITOSAN; DRUG DELIVERY SYSTEMS; HUMANS; LIPIDS; NANOPARTICLES; PHARMACEUTICAL PREPARATIONS; POLYETHYLENE GLYCOLS; POLYMERS;

EID: 84959045203     PISSN: 17425247     EISSN: 17447593     Source Type: Journal    
DOI: 10.1517/17425247.2016.1151872     Document Type: Review

References (131)

1. Bergström CAS, Holm R, Jørgensen SA, et al. Early pharmaceutical profiling to predict oral drug absorption: current status and unmet needs. Eur J Pharm Sci. 2014; 57: 173-199. doi: 10.1016/j.ejps.2013.10.015.
2. Plapied L, Duhem N, Des Rieux A, et al. Fate of polymeric nanocarriers for oral drug delivery. Curr Opin Colloid Interface Sci. 2011; 16: 228-237. doi: 10.1016/j.cocis.2010.12.005.
3. Di L, Fish PV, Mano T. Bridging solubility between drug discovery and development. Drug Discov Today. 2012; 17: 486-495. doi: 10.1016/j.drudis.2011.11.007.
4. Williams HD, Trevaskis NL, Charman SA, et al. Strategies to address low drug solubility in discovery and development. Pharmacol Rev. 2013; 65: 315-499.
5. Chakraborty S, Shukla D, Mishra B, et al. Lipid-an emerging platform for oral delivery of drugs with poor bioavailability. Eur J Pharm Biopharm. 2009; 73: 1-15. doi: 10.1016/j.ejpb.2009.06.001.
6. Desai PP, Date AA, Patravale VB. Overcoming poor oral bioavailability using nanoparticle formulations-opportunities and limitations. Drug Discov Today: Technol. 2012; 9: e87-95. doi: 10.1016/j.ddtec.2011.12.001.
7. Des Rieux A, Fievez V, Garinot M, et al. Nanoparticles as potential oral delivery systems of proteins and vaccines: A mechanistic approach. J Control Release. 2006; 116: 1-27. doi: 10.1016/j.jconrel.2006.08.013.
8. Soppimath KS, Aminabhavi TM, Kulkarni AR, et al. Biodegradable polymeric nanoparticles as drug delivery devices. J Control Release. 2001; 70: 1-20.
9. Shukla D, Chakraborty S, Singh S, et al. Lipid-based oral multiparticulate formulations-advantages, technological advances and industrial applications. Expert Opin Drug Deliv. 2011; 8: 207-224. doi: 10.1517/17425247.2011.547469.
10. Farokhzad OC, Langer R. Impact of nanotechnology on drug delivery. ACS Nano. 2009; 3: 16-20. doi: 10.1021/nn900002m.
11. Maher S, Ryan KB, Ahmad T, et al. Nanostructures overcoming the intestinal barrier: physiological considerations and mechanistic issues. In: Alonso MJ, Csaba NS, editors. Nanostructured biomaterials for overcoming biological barriers. Cambridge: The Royal Society of Chemistry; 2012. p. 39-62. doi: 10.1039/9781849735292-00039.
12. Morishita M, Peppas NA. Is the oral route possible for peptide and protein drug delivery? Drug Discov Today. 2006; 11: 905-910. doi: 10.1016/j.drudis.2006.08.005.
13. Charman WN. Lipids, lipophilic drugs, and oral drug delivery-some emerging concepts. J Pharm Sci. 2000; 89: 967-978.
14. Porter CJH, Trevaskis NL, Charman WN. Lipids and lipid-based formulations: optimizing the oral delivery of lipophilic drugs. Nat Rev Drug Discov. 2007; 6: 231-248. doi: 10.1038/nrd2197.
15. Pouton CW, Porter CJH. Formulation of lipid-based delivery systems for oral administration: materials, methods and strategies. Adv Drug Deliv Rev. 2008; 60: 625-637. doi: 10.1016/j.addr.2007.10.010.
16. Rao S, Tan A, Thomas N, et al. Perspective and potential of oral lipid-based delivery to optimize pharmacological therapies against cardiovascular diseases. J Control Release. 2014; 193: 174-187. doi: 10.1016/j.jconrel.2014.05.013.
17. Fricker G, Kromp T, Wendel A, et al. Phospholipids and lipid-based formulations in oral drug delivery. Pharm Res. 2010; 27: 1469-1486. doi: 10.1007/s11095-010-0130-x.
18. Manosroi A, Bauer KH. Effects of gastrointestinal administration of human insulin and a human insulin-deae-dextran complex entrapped in different compound liposomes on blood glucose in rats. Drug Dev Ind Pharm. 1990; 16: 1521-1538. doi: 10.3109/03639049009074381.
19. Mohsin K, Long MA, Pouton CW. Design of lipid-based formulations for oral administration of poorly water-soluble drugs: precipitation of drug after dispersion of formulations in aqueous solution. J Pharm Sci. 2009; 98: 3582-3595. doi: 10.1002/jps.21659.
20. Ryan KB, Maher S, Brayden DJ, et al. Nanostructures overcoming the intestinal barrier: drug delivery strategies. In: Alonso MJ, Csaba NS., editors. Nanostructured biomaterials for overcoming biological barriers. Cambridge: The Royal Society of Chemistry; 2012. p. 63-90. doi: 10.1039/9781849735292-00063.
21. Raemdonck K, Braeckmans K, Demeester J, et al. Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery. Chem Soc Rev. 2014; 43: 444-472. doi: 10.1039/c3cs60299k.
22. Cheow WS, Hadinoto K. Enhancing encapsulation efficiency of highly water-soluble antibiotic in poly(lactic-co-glycolic acid) nanoparticles: modifications of standard nanoparticle preparation methods. Colloid Surf A. 2010; 370: 79-86. doi: 10.1016/j.colsurfa.2010.08.050.
23. Alonso MJ, Couvreur P. Historical view of the design and development of nanocarriers for overcoming biological barriers. In: Alonso MJ, Csaba NS., editors. Nanostructured biomaterials for overcoming biological barriers. Cambridge: The Royal Society of Chemistry; 2012. p. 3-36. doi: 10.1039/9781849735292-00003.
24. Yechezkel CB. Doxil®-the first FDA-approved nano-drug. In: Peer D., editor. Handbook of harnessing biomaterials in nanomedicine. Singapore: Pan Stanford Publishing; 2012. p. 335-398. doi: 10.1201/b11620-13.
25. Barenholz Y. Doxil®-the first FDA-approved nano-drug: lessons learned. J Control Release. 2012; 160: 117-134. doi: 10.1016/j.jconrel.2012.03.020.
26. Luo Y, Teng Z, Li Y, et al. Solid lipid nanoparticles for oral drug delivery: chitosan coating improves stability, controlled delivery, mucoadhesion and cellular uptake. Carbohydr Polymers. 2015; 122: 221-229. doi: 10.1016/j.carbpol.2014.12.084.
27. Venishetty VK, Chede R, Komuravelli R, et al. Design and evaluation of polymer coated carvedilol loaded solid lipid nanoparticles to improve the oral bioavailability: A novel strategy to avoid intraduodenal administration. Colloid Surf B. 2012; 95: 1-9. doi: 10.1016/j.colsurfb.2012.01.001.
28. Sugihara H, Yamamoto H, Kawashima Y, et al. Effectiveness of submicronized chitosan-coated liposomes in oral absorption of indomethacin. J Liposome Res. 2012; 22: 72-79. doi: 10.3109/08982104.2011.621128.
29. Feeney OM, Williams HD, Pouton CW, et al. Stealth lipid-based formulations: poly(ethylene glycol)-mediated digestion inhibition improves oral bioavailability of a model poorly water soluble drug. J Control Release. 2014; 192: 219-227. doi: 10.1016/j.jconrel.2014.07.037.
30. Jain S, Kumar D, Swarnakar NK, et al. Polyelectrolyte stabilized multilayered liposomes for oral delivery of paclitaxel. Biomaterials. 2012; 33: 6758-6768. doi: 10.1016/j.biomaterials.2012.05.026.
31. Ying X-Y, Cui D, Yu L, et al. Solid lipid nanoparticles modified with chitosan oligosaccharides for the controlled release of doxorubicin. Carbohydr Polymers. 2011; 84: 1357-1364. doi: 10.1016/j.carbpol.2011.01.037.
32. Yuan H, Chen C-Y, Chai G-H, et al. Improved transport and absorption through gastrointestinal tract by PEGylated solid lipid nanoparticles. Mol Pharm. 2013; 10: 1865-1873. doi: 10.1021/mp300649z.
33. Jain S, Patil SR, Swarnakar NK, et al. Oral delivery of doxorubicin using novel polyelectrolyte-stabilized liposomes (Layersomes). Mol Pharm. 2012; 9: 2626-2635. doi: 10.1021/mp300202c.
34. Beloqui A, Solinís MÁ, Rieux A, et al. Dextran-protamine coated nanostructured lipid carriers as mucus-penetrating nanoparticles for lipophilic drugs. Int J Pharm. 2014; 468: 105-111. doi: 10.1016/j.ijpharm.2014.04.027.
35. Fonte P, Nogueira T, Gehm C, et al. Chitosan-coated solid lipid nanoparticles enhance the oral absorption of insulin. Drug Deliv and Transl Res. 2011; 1: 299-308. doi: 10.1007/s13346-011-0023-5.
36. Sarmento B, Mazzaglia D, Bonferoni MC, et al. Effect of chitosan coating in overcoming the phagocytosis of insulin loaded solid lipid nanoparticles by mononuclear phagocyte system. Carbohydr Polymers. 2011; 84: 919-925. doi: 10.1016/j.carbpol.2010.12.042.
37. Garcia-Fuentes M, Torres D, Alonso MJ. New surface-modified lipid nanoparticles as delivery vehicles for salmon calcitonin. Int J Pharm. 2005; 296: 122-132. doi: 10.1016/j.ijpharm.2004.12.030.
38. Huang A, Makhlof A, Ping Q, et al. N-trimethyl chitosan-modified liposomes as carriers for oral delivery of salmon calcitonin. Drug Deliv. 2011; 18: 562-569. doi: 10.3109/10717544.2011.596585.
39. Gradauer K, Barthelmes J, Vonach C, et al. Liposomes coated with thiolated chitosan enhance oral peptide delivery to rats. J Control Release. 2013; 172: 872-878. doi: 10.1016/j.jconrel.2013.10.011.
40. Takeuchi H, Matsui Y, Sugihara H, et al. Effectiveness of submicron-sized, chitosan-coated liposomes in oral administration of peptide drugs. Int J Pharm. 2005; 303: 160-170. doi: 10.1016/j.ijpharm.2005.06.028.
41. Guo J, Ping Q, Jiang G, et al. Chitosan-coated liposomes: characterization and interaction with leuprolide. Int J Pharm. 2003; 260: 167-173.
42. Galović Rengel R, Barišić K, Pavelić Ž, et al. High efficiency entrapment of superoxide dismutase into mucoadhesive chitosan-coated liposomes. Eur J Pharm Sci. 2002; 15: 441-448.
43. Takeuchi H, Matsui Y, Yamamoto H, et al. Mucoadhesive properties of carbopol or chitosan-coated liposomes and their effectiveness in the oral administration of calcitonin to rats. J Control Release. 2003; 86: 235-242.
44. Werle M, Takeuchi H. Chitosan-aprotinin coated liposomes for oral peptide delivery: Development, characterisation and in vivo evaluation. Int J Pharm. 2009; 370: 26-32. doi: 10.1016/j.ijpharm.2008.11.013.
45. Minato S, Iwanaga K, Kakemi M, et al. Application of polyethyleneglycol (PEG)-modified liposomes for oral vaccine: effect of lipid dose on systemic and mucosal immunity. J Control Release. 2003; 89: 189-197.
46. Li H, Song JH, Park JS, et al. Polyethylene glycol-coated liposomes for oral delivery of recombinant human epidermal growth factor. Int J Pharm. 2003; 258: 11-19.
47. Iwanaga K, Ono S, Narioka K, et al. Oral delivery of insulin by using surface coating liposomes: Improvement of stability of insulin in GI tract. Int J Pharm. 1997; 157: 73-80. doi: 10.1016/S0378-5173(97)00237-8.
48. Agrawal AK, Harde H, Thanki K, et al. Improved stability and antidiabetic potential of insulin containing folic acid functionalized polymer stabilized multilayered liposomes following oral administration. Biomacromolecules. 2014; 15: 350-360. doi: 10.1021/bm401580k.
49. Harde H, Siddhapura K, Agrawal AK, et al. Development of dual toxoid-loaded layersomes for complete immunostimulatory response following peroral administration. Nanomedicine. 2015; 10: 1077-1091. doi: 10.2217/nnm.14.177.
50. Makhlof A, Fujimoto S, Tozuka Y, et al. In vitro and in vivo evaluation of WGA-carbopol modified liposomes as carriers for oral peptide delivery. Eur J Pharm Biopharm. 2011; 77: 216-224. doi: 10.1016/j.ejpb.2010.12.008.
51. Müller RH, Mäder K, Gohla S. Solid lipid nanoparticles (SLN) for controlled drug delivery-a review of the state of the art. Eur J Pharm Biopharm. 2000; 50: 161-177.
52. Wan F, You J, Sun Y, et al. Studies on PEG-modified SLNs loading vinorelbine bitartrate (I): preparation and evaluation in vitro. Int J Pharm. 2008; 359: 104-110. doi: 10.1016/j.ijpharm.2008.03.030.
53. Gref R, Lück M, Quellec P, et al. Stealth corona-core nanoparticles surface modified by polyethylene glycol (PEG): influences of the corona (PEG chain length and surface density) and of the core composition on phagocytic uptake and plasma protein adsorption. Colloid Surf B. 2000; 18: 301-313. doi: 10.1016/S0927-7765(99)00156-3.
54. Hu F-Q, Jiang S-P, Du Y-Z, et al. Preparation and characterization of stearic acid nanostructured lipid carriers by solvent diffusion method in an aqueous system. Colloids Surf B: Biointerfaces. 2005; 45: 167-173. doi: 10.1016/j.colsurfb.2005.08.005.
55. Paliwal R, Rai S, Vaidya B, et al. Effect of lipid core material on characteristics of solid lipid nanoparticles designed for oral lymphatic delivery. Nanomedicine. 2009; 5: 184-191. doi: 10.1016/j.nano.2008.08.003.
56. Jani P, Halbert GW, Langridge J, et al. Nanoparticle uptake by the rat gastrointestinal mucosa: quantitation and particle size dependency. J PharmPharmacol. 1990; 42: 821-826.
57. Knop K, Hoogenboom R, Fischer D, et al. Poly(ethylene glycol) in drug delivery: pros and cons as well as potential alternatives. Angew Chem Int Ed Engl. 2010; 49: 6288-6308. doi: 10.1002/anie.200902672.
58. Veronese FM, Pasut G. PEGylation, successful approach to drug delivery. Drug Discov Today. 2005; 10: 1451-1458. doi: 10.1016/S1359-6446(05)03575-0.
59. Dünnhaupt S, Kammona O, Waldner C, et al. Nano-carrier systems: strategies to overcome the mucus gel barrier. Eur J Pharm Biopharm. 2015; 96: 447-453. doi: 10.1016/j.ejpb.2015.01.022.
60. Smart JD. The basics and underlying mechanisms of mucoadhesion. Adv Drug Deliv Rev. 2005; 57: 1556-1568. doi: 10.1016/j.addr.2005.07.001.
61. Clausen A, Kast C, Bernkop-Schnürch A. The role of glutathione in the permeation enhancing effect of thiolated polymers. Pharm Res. 2002; 19: 602-608.
62. Werle M, Hoffer M. Glutathione and thiolated chitosan inhibit multidrug resistance P-glycoprotein activity in excised small intestine. J Control Release. 2006; 111: 41-46. doi: 10.1016/j.jconrel.2005.11.011.
63. Clark MA, Jepson MA, Hirst BH. Exploiting M cells for drug and vaccine delivery. Adv Drug Deliv Rev. 2001; 50: 81-106.
64. Gebert A, Rothkötter H-J. Pabst R. M cells in Peyer's patches of the intestine. Int Rev Cytol. 1996; 167: 91-159. doi: 10.1016/S0074-7696(08)61346-7.
65. Champion JA, Walker A, Mitragotri S. Role of particle size in phagocytosis of polymeric microspheres. Pharm Res. 2008; 25: 1815-1821. doi: 10.1007/s11095-008-9562-y.
66. Pandita D, Kumar S, Lather V. Hybrid poly(lactic-co-glycolic acid) nanoparticles: design and delivery prospectives. Drug Discov Today. 2015; 20: 95-104. doi: 10.1016/j.drudis.2014.09.018.
67. Zou P, Stern S, Sun D. PLGA/liposome hybrid nanoparticles for short-chain ceramide delivery. Pharm Res. 2014; 31: 684-693. doi: 10.1007/s11095-013-1190-5.
68. Liu Y, Pan J, Feng-S-S. Nanoparticles of lipid monolayer shell and biodegradable polymer core for controlled release of paclitaxel: effects of surfactants on particles size, characteristics and in vitro performance. Int J Pharm. 2010; 395: 243-250. doi: 10.1016/j.ijpharm.2010.05.008.
69. Li X, Guo S, Zhu C, et al. Intestinal mucosa permeability following oral insulin delivery using core shell corona nanolipoparticles. Biomaterials. 2013; 34: 9678-9687. doi: 10.1016/j.biomaterials.2013.08.048.
70. Ma T, Wang L, Wang D, et al. PLGA-lipid liposphere as a promising platform for oral delivery of proteins. Colloid Surf B. 2014; 117: 512-519. doi: 10.1016/j.colsurfb.2014.02.039.
71. Ma T, Wang L, Yang T, et al. M-cell targeted polymeric lipid nanoparticles containing a toll-like receptor agonist to boost oral immunity. Int J Pharm. 2014; 473: 296-303. doi: 10.1016/j.ijpharm.2014.06.052.
72. Cheow WS, Hadinoto K. Factors affecting drug encapsulation and stability of lipid-polymer hybrid nanoparticles. Colloid Surf B. 2011; 85: 214-220. doi: 10.1016/j.colsurfb.2011.02.033.
73. Troutier A-L, Delair T, Pichot C, et al. Physicochemical and interfacial investigation of lipid/polymer particle assemblies. Langmuir. 2005; 21: 1305-1313. doi: 10.1021/la047659t.
74. Fang RH, Aryal S, Hu C-MJ, et al. Quick synthesis of lipid-polymer hybrid nanoparticles with low polydispersity using a single-step sonication method. Langmuir. 2010; 26: 16958-16962. doi: 10.1021/la103576a.
75. Zhang L, Chan JM, Gu FX, et al. Self-assembled lipid-polymer hybrid nanoparticles: a robust drug delivery platform. ACS Nano. 2008; 2: 1696-1702. doi: 10.1021/nn800275r.
76. Feng-S-S, Mu L, Chen B-H, et al. Polymeric nanospheres fabricated with natural emulsifiers for clinical administration of an anticancer drug paclitaxel (Taxol®). Mater Sci Eng C Mater Biol Appl. 2002; 20: 85-92. doi: 10.1016/S0928-4931(02)00017-6.
77. García-Díaz M, Foged C, Nielsen HM. Improved insulin loading in poly(lactic-co-glycolic) acid (PLGA) nanoparticles upon self-assembly with lipids. Int J Pharm. 2015; 482: 84-91. doi: 10.1016/j.ijpharm.2014.11.047.
78. Yu F, Li Y, Liu CS, et al. Enteric-coated capsules filled with mono-disperse micro-particles containing PLGA-lipid-PEG nanoparticles for oral delivery of insulin. Int J Pharm. 2015; 484: 181-191. doi: 10.1016/j.ijpharm.2015.02.055.
79. Chan JM, Zhang L, Yuet KP, et al. PLGA-lecithin-PEG core-shell nanoparticles for controlled drug delivery. Biomaterials. 2009; 30: 1627-1634. doi: 10.1016/j.biomaterials.2008.12.013.
80. Salvador-Morales C, Zhang L, Langer R, et al. Immunocompatibility properties of lipid-polymer hybrid nanoparticles with heterogeneous surface functional groups. Biomaterials. 2009; 30: 2231-2240. doi: 10.1016/j.biomaterials.2009.01.005.
81. Ensign LM, Cone R, Hanes J. Oral drug delivery with polymeric nanoparticles: The gastrointestinal mucus barriers. Adv Drug Deliv Rev. 2012; 64: 557-570. doi: 10.1016/j.addr.2011.12.009.
82. Wang-Y-Y, Lai SK, Suk JS, et al. Addressing the PEG mucoadhesivity paradox to engineer nanoparticles that "slip" through the human mucus barrier. Angew Chem Int Ed Engl. 2008; 47 (50): 9726-9729. doi: 10.1002/anie.200803526
83. Regen SL, Czech B, Singh A. Polymerized vesicles. J Am Chem Soc. 1980; 102: 6638-6640. doi: 10.1021/ja00541a078.
84. Hub H-H, Hupfer B, Koch H, et al. Polymerizable phospholipid analogues-new stable biomembrane and cell models. Angew Chem Int Ed Engl. 1980; 19: 938-940. doi: 10.1002/anie.198009381.
85. Okada J, Cohen S, Langer R. In vitro evaluation of polymerized liposomes as an oral drug delivery system. Pharm Res. 1995; 12: 576-582.
86. Guo C, Liu S, Jiang C, et al. A promising drug controlled-release system based on diacetylene/phospholipid polymerized vesicles. Langmuir. 2009; 25: 13114-13119. doi: 10.1021/la9034112.
87. Chen H, Torchilin V, Langer R. Polymerized liposomes as potential oral vaccine carriers: stability and bioavailability. J Control Release. 1996; 42: 263-272. doi: 10.1016/0168-3659(96)01459-9.
88. Ann Clark M, Blair H, Liang L, et al. Targeting polymerised liposome vaccine carriers to intestinal M cells. Vaccine. 2001; 20: 208-217.
89. Chen H, Torchilin V, Langer R. Lectin-bearing polymerized liposomes as potential oral vaccine carriers. Pharm Res. 1996; 13: 1378-1383.
90. Joyce P, Whitby CP, Prestidge CA. Bioactive hybrid particles from poly(d,l-lactide-co-glycolide) nanoparticle stabilized lipid droplets. ACS Appl Mater Interfaces. 2015; 7: 17460-17470. doi: 10.1021/acsami.5b05068.
91. Toorisaka E, Hashida M, Kamiya N, et al. An enteric-coated dry emulsion formulation for oral insulin delivery. J Control Release. 2005; 107: 91-96. doi: 10.1016/j.jconrel.2005.05.022.
92. Nassar T, Attili-Qadri S, Harush-Frenkel O, et al. High plasma levels and effective lymphatic uptake of docetaxel in an orally available nanotransporter formulation. Cancer Res. 2011; 71: 3018-3028. doi: 10.1158/0008-5472.CAN-10-3118.
93. Attili-Qadri S, Karra N, Nemirovski A, et al. Oral delivery system prolongs blood circulation of docetaxel nanocapsules via lymphatic absorption. Proc Nati Acad Sci USA. 2013; 110: 17498-17503. doi: 10.1073/pnas.1313839110.
94. Rao S, Richter K, Nguyen T-H, et al. Pluronic-functionalized silica lipid hybrid microparticles: improving the oral delivery of poorly water-soluble weak bases. Mol Pharm. 2015; 12: 4424-4433. doi: 10.1021/acs.molpharmaceut.5b00622.
95. Su Y-L, Li J-R, Jiang L. A study on the interactions of surfactants with phospholipid/polydiacetylene vesicles in aqueous solutions. Colloid Surf A. 2005; 257-258: 25-30. doi: 10.1016/j.colsurfa.2004.10.058.
96. Lee S-M, Chen H, Dettmer CM, et al. Polymer-caged lipsomes: A pH-responsive delivery system with high stability. J Am Chem Soc. 2007; 129: 15096-15097. doi: 10.1021/ja070748i.
97. Lee S-M, Ahn RW, Chen F, et al. Biological evaluation of pH-responsive polymer-caged nanobins for breast cancer therapy. ACS Nano. 2010; 4: 4971-4978. doi: 10.1021/nn100560p.
98. Lee S-M, Lee O-S, OHalloran TV, et al. Triggered release of pharmacophores from [Ni(HAsO)]-loaded polymer-caged nanobin enhances pro-apoptotic activity: a combined experimental and theoretical study. ACS Nano. 2011; 5: 3961-3969. doi: 10.1021/nn200478m.
99. Lee S-M, OHalloran TV, Nguyen ST. Polymer-caged nanobins for synergistic cisplatin-doxorubicin combination chemotherapy. J Am Chem Soc. 2010; 132: 17130-17138. doi: 10.1021/ja107333g.
100. Rao S, Tan A, Boyd BJ, et al. Synergistic role of self-emulsifying lipids and nanostructured porous silica particles in optimizing the oral delivery of lovastatin. Nanomedicine (Lond). 2014; 9: 2745-2759. doi: 10.2217/nnm.14.37.
101. Tan A, Eskandar N, Rao S, et al. First in man bioavailability and tolerability studies of a silica-lipid hybrid (Lipoceramic) formulation: a Phase I study with ibuprofen. Drug Deliv and Transl Res. 2014; 4: 212-221. doi: 10.1007/s13346-013-0172-9.
102. Tan A, Martin A, Nguyen T-H, et al. Hybrid nanomaterials that mimic the food effect: controlling enzymatic digestion for enhanced oral drug absorption. Angew Chem Int Ed. 2012; 51: 5475-5479. doi: 10.1002/anie.201200409.
103. Tan A, Prestidge C. Nanostructured silica-lipid hybrid microparticles: a supersaturating carrier for water-and lipid-resistant compounds. Chem Lett. 2012; 41: 1334-1336. doi: 10.1246/cl.2012.1334.
104. Tan A, Simovic S, Davey AK, et al. Silica nanoparticles to control the lipase-mediated digestion of lipid-based oral delivery systems. Mol Pharm. 2010; 7: 522-532. doi: 10.1021/mp9002442.
105. Tan A, Simovic S, Davey AK, et al. Silica-lipid hybrid (SLH) microcapsules: a novel oral delivery system for poorly soluble drugs. J Control Release. 2009; 134: 62-70. doi: 10.1016/j.jconrel.2008.10.014.
106. Dening T, Rao S, Thomas N, et al. Novel nanostructured solid materials for modulating oral drug delivery from solid-state lipid-based drug delivery systems. Aaps J. 2016;18(1):23-40. doi: 10.1208/s12248-015-9824-7
107. Tan A, Rao S, Prestidge C. Transforming lipid-based oral drug delivery systems into solid dosage forms: an overview of solid carriers, physicochemical properties, and biopharmaceutical performance. Pharm Res. 2013; 30: 2993-3017. doi: 10.1007/s11095-013-1107-3.
108. Yasmin R, Tan A, Bremmell KE, et al. Lyophilized silica lipid hybrid (SLH) carriers for poorly water-soluble drugs: physicochemical and in vitro pharmaceutical investigations. J Pharm Sci. 2014; 103: 2950-2959. doi: 10.1002/jps.23914.
109. Homar M, Šuligoj D, Gašperlin M. Preparation of microcapsules with self-microemulsifying core by a vibrating nozzle method. J Microencapsul. 2007; 24: 72-81. doi: 10.1080/02652040601058525.
110. Homar M, Dreu R, Kerč J, et al. Preparation and evaluation of celecoxib-loaded microcapsules with self-microemulsifying core. J Microencapsul. 2009; 26: 479-484. doi: 10.1080/02652040802383839.
111. Zvonar A, Berginc K, Kristl A, et al. Microencapsulation of self-microemulsifying system: improving solubility and permeability of furosemide. Int J Pharm. 2010; 388 (1-2): 151-158. doi: 10.1016/j.ijpharm.2009.12.055
112. You J, Cui F-D, Han X, et al. Study of the preparation of sustained-release microspheres containing zedoary turmeric oil by the emulsion-solvent-diffusion method and evaluation of the self-emulsification and bioavailability of the oil. Colloid Surf B. 2006; 48: 35-41. doi: 10.1016/j.colsurfb.2005.12.011.
113. You J, Cui F-D, Wang Y-S, et al. The study of the emulsification efficiency of aerosil and HPMCAS type and their ratio to stabilize emulsions of zedoary turmeric oil. Colloid Surf A. 2006; 280: 76-80. doi: 10.1016/j.colsurfa.2006.01.034.
114. You J, Cui F-D, Li Q-P, et al. A novel formulation design about water-insoluble oily drug: preparation of zedoary turmeric oil microspheres with self-emulsifying ability and evaluation in rabbits. Int J Pharm. 2005; 288: 315-323. doi: 10.1016/j.ijpharm.2004.10.005.
115. Chu BS, Rich GT, Ridout MJ, et al. Modulating pancreatic lipase activity with galactolipids: effects of emulsion interfacial composition. Langmuir. 2009; 25: 9352-9360. doi: 10.1021/la9008174.
116. Marvola M, Nykänen P, Rautio S, et al. Enteric polymers as binders and coating materials in multiple-unit site-specific drug delivery systems. Eur J Pharm Sci. 1999; 7: 259-267.
117. Dalmoro A, Lamberti G, Titomanlio G, et al. Enteric micro-particles for targeted oral drug delivery. AAPS PharmSciTech. 2010; 11: 1500-1507. doi: 10.1208/s12249-010-9528-3.
118. Pouton CW. Formulation of poorly water-soluble drugs for oral administration: physicochemical and physiological issues and the lipid formulation classification system. Eur J Pharm Sci. 2006; 29: 278-287. doi: 10.1016/j.ejps.2006.04.016.
119. Williams HD, Sassene P, Kleberg K, et al. Toward the establishment of standardized in vitro tests for lipid-based formulations, part 4: proposing a new lipid formulation performance classification system. J Pharm Sci. 2014; 103: 2441-2455. doi: 10.1002/jps.24067.
120. Williams H, Trevaskis N, Yeap Y, et al. Lipid-based formulations and drug supersaturation: harnessing the unique benefits of the lipid digestion/absorption pathway. Pharm Res. 2013; 30: 2976-2992. doi: 10.1007/s11095-013-1126-0.
121. Alhalaweh A, Ali HRH, Velaga SP. Effects of polymer and surfactant on the dissolution and transformation profiles of cocrystals in aqueous media. Cryst Grow Des. 2013; 14: 643-648. doi: 10.1021/cg4015256.
122. Guzmán HR, Tawa M, Zhang Z, et al. Combined use of crystalline salt forms and precipitation inhibitors to improve oral absorption of celecoxib from solid oral formulations. J Pharm Sci. 2007; 96: 2686-2702. doi: 10.1002/jps.20906.
123. Xu S, Dai W-G. Drug precipitation inhibitors in supersaturable formulations. Int J Pharm. 2013; 453: 36-43. doi: 10.1016/j.ijpharm.2013.05.013.
124. Vandecruys R, Peeters J, Verreck G, et al. Use of a screening method to determine excipients which optimize the extent and stability of supersaturated drug solutions and application of this system to solid formulation design. Int J Pharm. 2007; 342: 168-175. doi: 10.1016/j.ijpharm.2007.05.006.
125. Warren DB, Benameur H, Porter CJH, et al. Using polymeric precipitation inhibitors to improve the absorption of poorly water-soluble drugs: A mechanistic basis for utility. J Drug Target. 2010; 18: 704-731. doi: 10.3109/1061186X.2010.525652.
126. Anby MU, Williams HD, McIntosh M, et al. Lipid digestion as a trigger for supersaturation: evaluation of the impact of supersaturation stabilization on the in vitro and in vivo performance of self-emulsifying drug delivery systems. Mol Pharm. 2012; 9: 2063-2079. doi: 10.1021/mp300164u.
127. Song W, Park J, Yeom D, et al. Enhanced dissolution of celecoxib by supersaturating self-emulsifying drug delivery system (S-SEDDS) formulation. Arch Pharm Res. 2013; 36: 69-78. doi: 10.1007/s12272-013-0011-z.
128. Lee DH, Yeom DW, Song YS, et al. Improved oral absorption of dutasteride via Soluplus(®)-based supersaturable self-emulsifying drug delivery system (S-SEDDS). Int J Pharm. 2015; 478: 341-347. doi: 10.1016/j.ijpharm.2014.11.060.
129. Gao P, Akrami A, Alvarez F, et al. Characterization and optimization of AMG 517 supersaturatable self-emulsifying drug delivery system (S-SEDDS) for improved oral absorption. J Pharm Sci. 2009; 98: 516-528. doi: 10.1002/jps.21451.
130. Gao P, Guyton ME, Huang T, et al. Enhanced oral bioavailability of a poorly water soluble drug PNU-91325 by supersaturatable formulations. Drug Dev Ind Pharm. 2004; 30: 221-229. doi: 10.1081/DDC-120028718.
131. Gao P, Rush BD, Pfund WP, et al. Development of a supersaturable SEDDS (S-SEDDS) formulation of paclitaxel with improved oral bioavailability. J Pharm Sci. 2003; 92: 2386-2398. doi: 10.1002/jps.10511.